Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05601050
Other study ID # 20-0460
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 4, 2021
Est. completion date March 1, 2023

Study information

Verified date March 2023
Source Northwell Health
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Longitudinal observational study of the relationship between speech patterns and clinical symptoms in schizophrenia spectrum disorders.


Description:

The accurate prediction and tracking of clinical and functional outcomes in young people with schizophrenia-spectrum disorders is critical for delivering appropriate interventions and for understanding the brain mechanisms behind psychosis. Language is an optimal avenue for tracking psychosis processes because language is readily produced and captured, has well-established disruptions in psychosis, and known relationship to brain circuits. Using computers to automate detection of language features has the further advantage of being objective, quantitative, and adaptable into an efficient and cost-effective tool. The investigators propose to use automated linguistic analyses in young people early in the course of schizophrenia spectrum disorders to measure language features including fluency (speech rate), complexity (proportion of unique words), prosody (changes in tone during speech), and semantic coherence (how sequencing of words conform to expected patterns). The investigators will test whether these features meaningfully reflect clinical symptoms, cognition, and functioning, and whether they help predict how psychosis symptoms change over time.


Recruitment information / eligibility

Status Completed
Enrollment 77
Est. completion date March 1, 2023
Est. primary completion date March 1, 2023
Accepts healthy volunteers No
Gender All
Age group 15 Years to 40 Years
Eligibility Inclusion Criteria: - Speaks English with conversational proficiency - Current DSM-V-defined diagnosis of schizophrenia, schizophreniform, schizoaffective disorder, unspecified psychotic disorder, or brief psychotic disorder or bipolar 1 disorder with psychotic features or major depressive disorder with psychotic features using the Structured Clinical Interview for Axis I DSM-V Disorders (SCID-I/P). - Current significant positive or disorganized symptoms of psychosis (DSM 5 Criterion A) including rating at or above any of the following on the BPRS: - Grandiosity (Severe - 6) - Suspiciousness (Moderately Severe - 5) - Hallucinations (Moderately Severe - 5) - Unusual thought content (Moderate - 4) - Bizarre Behavior (Moderate - 4) - Disorientation (Moderate - 4) - Conceptual Disorganization (Moderate - 4) - Early phase of psychotic illness as defined by less than 2 years elapsed since reaching threshold for psychotic disorder - Age 15 to 40 years - Has capacity and willing to sign informed consent; if minor, parent is willing to give consent and child is willing to give assent. - Screening will not include a pregnancy test. Pregnant women will not be screened out of the study because the study procedures are of very low risk overall, and pregnancy does not place the participant or the fetus at any significant risk. - Minors will be included in the study because psychosis symptoms frequently onset before the age of 18 and this patient group is particularly in need of accurate prognosis and treatment. Therefore, it is of vital importance that the conclusions of the study be applicable to minors and that they be included among the participants. Exclusion Criteria: - Participants with substance-induced psychotic disorder, a psychotic disorder due to a general medical condition, delusional disorder, or shared psychotic disorder will not be included. - Patient currently under the influence of alcohol or drugs. - Disorders affecting speech or language, such as aphasia, intellectual disability (IQ<70), or language disorder, or movement disorders affecting speech like tardive dyskinesia, or physical impairments causing significant distortions to speech - Serious neurological or endocrine disorder or any medical condition or treatment known to affect the brain and/or language, including but not limited to: neurodegenerative disorders, traumatic brain injury with active symptoms, autism spectrum disorder, encephalitis, epilepsy - Significant risk of suicidal or homicidal behavior; - Cognitive or language limitations, or any other factor that would preclude subjects providing informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Other:
There is no intervention
There is no intervention

Locations

Country Name City State
United States Zucker Hillside Hospital Glen Oaks New York

Sponsors (2)

Lead Sponsor Collaborator
Northwell Health Winterlight Labs

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Speech features from the Winterlight Speech Assessment Acoustic and linguistic measures of speech computed based on performance on the Winterlight Speech Assessment. 6 months
Secondary Brief Psychiatric Rating Scale (BPRS) 18 item, range = 1, not observed - 7, very severe; higher scores resulting in worse outcome. 6 months
Secondary Hamilton Rating Scale for Depression 24 item, range = 0, absent - 4, severe; higher scores resulting in worse outcome. 6 months
Secondary Young Mania Rating Scale 11 item, range = 0, absent - 8, severe; higher scores resulting in worse outcome. 6 months
Secondary Scale for the Assessment of Negative Symptoms 22 item, range= 0, absent - 5, severe; higher scores resulting in worse outcome. 6 months
Secondary Scale for the Assessment of Thought Language and Communication 20 item, range= 0, absent - 3, severe; higher scores resulting in worse outcome. 6 month
See also
  Status Clinical Trial Phase
Completed NCT05083377 - Clozapine Use Pattern in the Province of Seville
Recruiting NCT06313918 - Exercise Therapy in Mental Disorders-study N/A
Recruiting NCT06134661 - Accelerated rTMS for Psychomotor Slowing N/A
Completed NCT01433094 - Study on Psychoeducation Enhancing Results of Adherence in Schizophrenia N/A
Terminated NCT05526833 - An Extension Protocol for Patients Who Previously Completed the TMS Pilot Study N/A
Recruiting NCT05982158 - Avatar-mediated Therapy Versus Cognitive Behavioural Therapy for Persisting Experiences of Hearing Voices N/A
Active, not recruiting NCT06175559 - Embedded Narrative in Interactive Game Design for Improving Medication Adherence of Schizophrenia N/A
Active, not recruiting NCT05673941 - "InMotion" - Physical Training With Creative Movement as an Intervention for Adults With Schizophrenia N/A
Recruiting NCT02916810 - TMS for Symptom Reduction in Schizophrenia N/A
Recruiting NCT05958875 - The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. Phase 4
Recruiting NCT03525054 - Semantic and Syntactic Computerized Analysis of Free Speech
Recruiting NCT05389345 - tDCS and Executive Function Training for Schizophrenia N/A
Completed NCT03075202 - Role of an E-cigarette on Smoking Displacement in Smokers With Schizophrenia
Completed NCT03921450 - Overcoming Psychomotor Slowing in Psychosis (OCoPS-P) N/A
Completed NCT06231407 - Increasing Medication Check Participation Through Applying CT-r N/A
Recruiting NCT04478838 - "Extended" (Alternate Day) Antipsychotic Dosing Phase 4
Completed NCT04366401 - Efficacy of Prebiotic and Probiotic Dietary Modulation in Schizophrenic Disorders N/A
Completed NCT04612777 - A Trial of "Opening Doors to Recovery" for Persons With Serious Mental Illnesses N/A
Not yet recruiting NCT06191965 - MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction Phase 2/Phase 3
Recruiting NCT04631939 - Metacognitive Training as a Serious Game N/A